Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy

HIV Medicine

Volumn 15, Issue 10, 2014, Pages 611-614

  Verbon, A ^a   Rijnders, B J A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiretroviral therapy; Drug resistance; HIV 1; Single tablet regimen

Indexed keywords

EFAVIRENZ; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; VIRUS RNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; EMTRICITABINE; NITRILE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ADULT; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MEDICATION COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS MUTATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; MALE; MUTATION; VIROLOGY; VIRUS LOAD;

ADENINE; ADULT; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; NITRILES; ORGANOPHOSPHONATES; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; YOUNG ADULT;

EID: 84911425127     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12157     Document Type: Article

References (9)

1. Azijn H, Tirry I, Vingerhoets J etal. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54: 718-727.
2. Palella FFM, Tabas P, Gazzard B, Ruane P, Van Lunzen J etal. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA suppressed participants. AIDS 2014; 28: 335-344.
3. Arasteh K, Rieger A, Yeni P etal. Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther 2009; 14: 713-722.
4. Stanford HIV Database. Algorithm on HIV mutations and drug susceptibility. Available at: http://hivdb.stanford.edu/ (accessed 20 October 2013).
5. Ngo-Giang-Huong N, Jourdain G, Amzal B etal. Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. PLoS ONE 2011; 6: e27427.
6. Asahchop EL, Wainberg MA, Oliveira M etal. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS 2013; 27: 879-887.
7. Anta L, Llibre JM, Poveda E etal. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013; 27: 81-85.
8. Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712-722.
9. Santoro M, Sabin C, Forbici F etal. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. HIV Med 2013; 14: 571-577.